Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Eight RNAi-Related Patent Applications: Jul 24, 2008

Title: Method and Medicament for Inhibiting the Expression of a Given Gene
Number: 20080171862 & 20080171861
Filed: Oct. 31, 2007
Lead Inventor: Roland Kreutzer, Alnylam Europe (Alnylam Pharmaceuticals)
The patent applications, their abstracts state, claim “an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.”

Title: RNAi-Mediated Inhibition of Aquaporin 1 for Treatment of IOP-Related Conditions
Number: 20080171719
Filed: Nov. 28, 2007
Lead Inventor: Jon Chatterton, Alcon
The patent application, its abstract states, claims “RNA interference … for inhibition of aquaporin 1 in intraocular pressure-related conditions, including ocular hypertension and glaucoma, such as normal-tension glaucoma and open-angle glaucoma.”

Title: Nucleic Acid Modulation of Toll-Like Receptor-Mediated Immune Stimulation
Number: 20080171716
Filed: Aug. 15, 2007
Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics (Tekmira Pharmaceuticals)
According to the patent application’s abstract, the invention “provides methods of modulating the activation of certain Toll-like receptors such as TLR7/8 using chemically modified nucleic acid molecules … [as well as] methods of using such modified nucleic acid molecules to treat diseases or disorders associated with TLR7/8 activation such as systemic lupus erythematosus.”
The abstract adds that the invention “further provides compositions comprising a combination of modified nucleic acid molecules and nucleic acid molecules that silence expression of one or more target sequences. Methods of using such compositions to reduce or abolish target gene expression without inducing cytokine production are also provided.”

Title: Methods and Compositions Involving miRNA and miRNA Inhibitor Molecules
Number: 20080171715
Filed: Aug. 10, 2007
Lead Inventor: David Brown, Ambion (Asuragen)
The invention “concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules,” the patent application’s abstract states. “Moreover, the … invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.”

Title: Methods and Compositions Involving microRNA
Number: 20080171667
Filed: Aug. 11, 2007
Lead Inventor: David Brown, Ambion (Asuragen)
The invention “concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis,” the patent application’s abstract states. “Moreover, the … invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.”

Title: Expression System
Number: 20080171358
Filed: June 1, 2005 PCT Filed: June 1, 2005
Inventor: Jacques Perrault, San Diego State University
The invention “relates generally to methods and compositions for expression of polypeptides or delivery of interfering RNAs in various cell types,” according to the patent application’s abstract.

Title: Highly Branched Hk Peptides as Effective Carriers of siRNA
Number: 20080171025
Filed: Nov. 17, 2005 PCT Filed: Nov. 17, 2005
Inventor: Archibald Mixson, University of Maryland School of Medicine
The invention, the patent application’s abstract states, “is directed to methods of transfecting cells with siRNA by contacting a transfection complex with one or more cells, where the transfection complex includes a transport polymer and siRNA. … The invention is also directed to such transfection complexes and to compositions that include such transfection complexes. The invention is further directed to methods of treating patients using the transfection complexes.”

Title: Macromolecular Compositions That Cross the Blood-Brain Barrier and Methods of Use Thereof
Number: 20080170994
Filed: Aug. 20, 2007
Lead Inventor: William Pardridge, Armagen Technologies
“The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier,” the patent application’s abstract claims. “Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease.”

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.